SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Annual Wellness Visit, Subsequent — Ida B. Wells — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientIda B. Wells
Date of birth1862-07-16
IdentifiersMRN HR-ET022-SYN-TD; SSN (made up) 000-22-5903
Document date1931-02-17
AuthorCordelia Ashworth-Banks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Subsequent annual wellness visit. [S]

History of Present Illness

Mrs. Wells comes for her subsequent annual wellness visit two weeks after starting dapagliflozin and four weeks after starting losartan for chronic kidney disease G3b A2 with hypertension. She has had no dizziness, faintness or genital itching and passes a little more urine than before. Her home blood pressure readings average 134/80. Her ankles no longer swell by evening, and she is less tired in the afternoons. Acetaminophen controls her knee aching and she has taken no naproxen since the first visit. Last week she went to the kidney education session at the health center, brought a page of questions, and asked to spend part of today on what the treatment options would mean for her if her kidneys failed one day. She has had no falls, emergency visits or hospital stays in the past year. [S]

ElementDetail
VisitSubsequent annual wellness visit, age 68
New medicinesLosartan for four weeks and dapagliflozin for two, without side effects
Home blood pressureAverage 134/80
SymptomsAnkle swelling gone; less tired
Safety eventsNo falls, emergency visits or hospital stays

Health risk assessment. Completed by her on paper before the visit and reviewed with her by Dr. Ashworth-Banks. [S]

DomainFinding
Self-rated healthFair; better than a month ago
PsychosocialLives with her husband; a wide circle of colleagues and readers; busy with writing and civic work; stress from deadlines is manageable
BehavioralNever smoker; under one drink a week; walks most days; cutting salt with help from the dietitian; sleeps about six and a half hours
Activities of daily livingIndependent in bathing, dressing, eating, toileting and transfers
Instrumental activities of daily livingManages her own medicines, money, correspondence and travel
Home safetySmoke detectors working; handrail on the front steps; no loose rugs
Hearing and visionHears well; reading glasses; last eye examination more than two years ago
BladderPasses a little more urine since dapagliflozin; no leakage
MemoryNo concerns
Health care experiencesWants to see the evidence and the numbers; says she was once told a kidney result was normal without anyone explaining how it was calculated

Review of Systems

SystemResultFinding
ConstitutionalPositiveTiredness in the afternoons, less than before; weight down 1.2 kg since intake
EyesNegativeNo change in vision with reading glasses
Ears, nose, mouth, and throatNegativeNo hearing difficulty; no mouth sores
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo nausea, poor appetite or blood in the stool
GenitourinaryNegativeNo burning, genital itching or blood in the urine
MusculoskeletalPositiveKnee aching on stairs, controlled with acetaminophen
IntegumentaryNegativeNo itching or rash
NeurologicalNegativeNo dizziness on standing, numbness or memory change
PsychiatricNegativeMood steady; PHQ-2 0
BreastNegativeNo lump or nipple change

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxenOne or two tablets up to three times a day as neededOral route1931-01-05activeS
Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eatingOne tablet daily, with sick-day rulesOral route1931-01-20 to 1931-03-03completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1931-01-20activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet dailyOne tablet dailyOral route1931-01-20activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgeryOne tablet daily, with sick-day rulesOral route1931-02-03activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1931-02-17Body height157cmS
1931-02-17Body weight69.2kgS
1931-02-17Body mass index (BMI) [Ratio]28.1kg/m2S
1931-02-17Systolic blood pressure136mm[Hg]S
1931-02-17Diastolic blood pressure82mm[Hg]S
1931-02-17Heart rate72/minS
1931-02-17Respiratory rate16/minS
1931-02-17Body temperature36.6CelS
1931-02-17Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1931-02-17Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1931-02-17Total score [Mini-Cog]5{score}S
1931-02-17Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 1931-02-17; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 69.2 kg; blood pressure 136/82 seated and 132/80 standing, without symptoms
EyesNear vision 20/30 with reading glasses; undilated fundi show mild arteriolar narrowing
EarsWhispered-voice test passed in both ears
NeckNo thyroid enlargement or nodes; no carotid bruits
CardiovascularRegular rhythm; no murmur; no ankle swelling
RespiratoryClear
AbdomenSoft; no masses or bruits
MusculoskeletalCrepitus in both knees without effusion; Timed Up and Go 11 seconds with a steady gait
NeurologicalOriented; Mini-Cog 5 of 5 (recall 3 of 3, clock normal)
SkinNo suspicious lesions
PsychiatricEngaged, exact and well informed; judgment intact

Problems

ProblemClinical statusVerificationCodeProvenance
Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be establishedresolvedconfirmed R94.4S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney diseaseactiveconfirmed I12.9S — Synthetic modern diagnosis; no blood pressure from her life is recorded.
Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7%activeconfirmed N18.32S — Synthetic modern diagnosis linked to the kidney disease recorded at her death.
Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tirednessactiveconfirmed D63.1S — Synthetic laboratory finding.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normalactiveconfirmed E55.9S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Depression screeningCompleted todayPHQ-2 score 0
Alcohol misuse screeningCompleted todayAUDIT-C score 1
Cognitive assessmentCompleted todayMini-Cog 5 of 5
Falls preventionCompleted todayNo falls; Timed Up and Go 11 seconds; home safety reviewed
Breast cancer screeningOrderedMammogram every two years to 74; last one more than two years ago
Colorectal cancer screeningOrderedStool immunochemical test, her choice, to avoid bowel preparation fluids and sedation while her kidney medicines are new
Bone density (DXA)OrderedWomen 65 and older; none on record; kidney disease adds to fracture risk
Hepatitis C and HIV screeningUp to dateBoth negative with the kidney tests last month
Influenza vaccine, this seasonUp to dateHigh-dose vaccine last month
Pneumococcal vaccineUp to datePCV20 last month; no further doses
Hepatitis B vaccineCompleted todayDose 2 of HepB-CpG today; series complete; antibody check after the series because of kidney disease
RSV vaccineCompleted todaySingle dose for an adult under 75 with chronic kidney disease
Recombinant zoster vaccineCompleted todayDose 1 today; dose 2 in two to six months
COVID-19 vaccine, this seasonDueAt the next visit, to space the vaccines at her request
Tetanus boosterUp to dateTdap six years ago
Eye examinationDueMore than two years since the last; dilated examination for hypertensive retinal changes
Lung cancer and abdominal aortic aneurysm screeningNot indicatedNever smoker
Cervical cancer screeningNot indicatedNot recommended after 65 with adequate prior screening, which she reports

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Respiratory syncytial virus vaccine, adjuvanted (RSVPreF3), single dose; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Adult Immunization Schedule by Age (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Breast Cancer: Screening (2024); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)

Follow-up: Review in two weeks with potassium and creatinine. Mammogram, bone density scan and stool test as ordered. Next annual wellness visit in one year. Next scheduled visit 1931-03-03: four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 25 minutes, with her consent, building on the kidney education session. She understands that her kidney disease is at stage G3b and that, with treatment, most people at her stage do not reach kidney failure; the estimate of her own 5-year risk was explained as about 7 in 100. If her kidneys were to fail, she would want to be assessed for a transplant, would prefer home dialysis to center dialysis if dialysis were needed, and wants conservative kidney management explained to her again before any choice is made. She wants full treatment for illness that can be reversed. She has named a health care agent, recorded in the confidential part of the chart and not named here. To be revisited yearly, at any sustained fall in eGFR below 20, or after a serious illness. [S]